Are the diagnostic criteria for antiphospholipid syndrome possible to define?;Czy ustalenie kryteriów diagnostycznych dla zespołu antyfosfolipidowego jest możliwe?

Reumatologia

Volumn 44, Issue 2, 2006, Pages 87-94

  Zimmermann Górska, Irena ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; DISEASE CLASSIFICATION; REVIEW; SCORING SYSTEM; THROMBOSIS;

EID: 33646888667     PISSN: 00346233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Piette JC. 1996 diagnostic and classification criteria for the antiphospholipid/cofactors syndrome: a "mission impossible?". Lupus 1996; 5: 354-63.
2. Rudwailet M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis. Arthritis Rheum 2005; 52: 1000-8.
3. Harris EN, Baguley E, Asherson RA, et al. Clinical and serological features of the "antiphospholipid syndrome". Br J Rheumatol 1987; 26 (suppl. 2): 19.
4. Hughes GRV. The anticardiolipin syndrome. Clin Exp Rheumatol 1985; 3: 285-6.
5. Alarćon-Segovia D, Deleze M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. Medicine 1989; 68: 353-65.
6. Alarćon-Segovia D, Perez-Vazquez ME, Villa AR, et al. Preliminary classification for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992; 21: 275-86.
7. Piette JC, Wechsler B, Bletry O, et al. Quels critéres pour le diagnostic du syndrome des antiphospholipides? Rev Med Interne 1993; 14: 799-803.
8. Asherson RA, Piette JC, Cervera R. "Primary", "secondary", "catastrophic", and other variants of the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, et al. (eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996; 249-58.
9. Andrews PA, Frampton G, Cameron JS. Antiphospholipid syndrome and systemic lupus erythematosus. Lancet 1993; 342: 988-9.
10. Mujic F. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. J Rheumatol 1995; 22: 1589-92.
11. Jȩdryka-Góral A, Małdykowa H, Chwalińska- Sadowska H i wsp. Zespół antyfosfolipidowy u chorych na toczeń rumieniowaty układowy. Znaczenie kliniczne izotypów przeciwciał aCL. Reumatologia 1994; 32: 103-9.
12. Luft S, Fronczek D, Jȩdryka-Góral A, et al. Badania nad wystȩpowaniem przeciwciał przeciw kardiolipinie u chorych na układowe choroby tkanki ta̧cznej. Reumatologia 1990; 28: 161-9.
13. Zimmermann-Górska I, Puszczewicz M, Luft S, et al. Familial studies in antiphospholipid syndrome. EULAR Symposium on Vasculitis, 1994; 82.
14. Zimmermann-Górska I, Puszczewicz M, Luft S i wsp. Objawy zespołu przeciwciał przeciwfosfolipidowych wystȩpuja̧ ce rodzinnie. Reumatologia 1995; 33: 202.
15. Wilson WA, Gharavi AE, Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-11.
16. Cervera R, Piette JCh, Font J, et al. Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1.000 patients. Arthritis Rheum 2002; 46: 1019-27.
17. Zimmermann-Górska I. Zespót antyfosfolipidowy - wielospecjalistyczny problem kliniczny. Twój Magazyn Medyczny 2005; 10: 6-11.
18. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4: 295-306.
19. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530-4.
20. Cervera R, Font J, Gomez-Puerta JA. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 2005; 64: 1205-9.
21. Shoenfeld Y, Blank M, Cervera R, et al. Infection origin of the antiphospholipid syndrome. Ann Rheum Dis 2006; 65: 2-6.
22. Yasuda S, Atsumi T, Matsuura E, et al. Significance of valine/leucine 247 polymorphism of beta 2 glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-beta2 glycoprotein I autoantibodies to the valine 247 beta 2-glycoprotein I variant. Arthritis Rheum 2005; 52: 212-8.
23. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement-dependent and requires a priming factor. Blood 2005; 106: 2340-6.
24. Zhang J, McCrae Kr. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2-glycoprotein I antibodies. Blood 2005; 105: 1964-9.
25. Simoncini S, Sapet C, Camoin-Jan L, et al. Role of reactive oxygen species and p 38 MAPK in the induction of the proadhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome. Int Immunol 2005; 17: 489-580.
26. Gomez-Puerta JA, Martin H, Amigo MC, et. al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 2005; 84: 225-30.
27. Freitas MV, da Silva LM, Deghaide NH, el. al. Is HLA class II susceptibility to primary antiphospholipid syndrome different from susceptibility to secondary antiphospholipid syndrome? Lupus 2004; 13: 125-31.
28. Meissner M, Chwalińska-Sadowska H. Clinical and serological evaluation of the secondary antiphospholipid syndrome patients (SAPS) in the course of SLE and primary antiphospholipid syndrome patients (PAPS) for the presence of vasculitis or vasculopathy. Ann Rheum Dis 2003; Suppl., 62.
29. Veras K, Lakos G, Kerenyi A, et al. Antiphospholipid antibodies in acute coronary syndrome. Lupus 2004; 13: 423-7.
30. Meissner M, Butkiewicz L, Chwalińska-Sadowska H. Zespół antyfosfolipidowy pierwotny (PARS) i wtórny do tocznia rumieniowatego układowego (SAPS) a miażdżyca tȩtnic; wstȩpna obserwacja. Reumatologia 2005; 43: 48-56.
31. Meissner M, Chwalińska-Sadowska H, Butkiewicz L i wsp. Zespół antyfosfolipidowy (APS) pierwotny (PAPS) i wtórny (SAPS) jako czynnik ryzyka miażdżycy. Twȯj Magazyn Medyczny 2005; 3: 49-53.
32. George J, Blank M, Hojnik M, et al. Oxidised low density lipoprotein (oxLDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome. Clin Exp Immunol 1997; 108: 227-33.
33. George J, Shoenfeld Y. The anti-phospholipid (Hughes) syndrome: a crossroad of autoimmunity and atherosclerosis. Lupus 1997; 6: 559-60.
34. Damoiseaux J, Jeyasekharan AD, Theunissen R, et al. Cross-reactivity of IgM and IgG anticardiolipin antibodies with oxidized - low density lipoproteins. Ann NY Acad Sci 2005; 1050: 163-9.
35. Bertolaccini ML, Atsumi T, Koike T, et al. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost 2005; 93: 289-97.
36. Hughes GR. Seronegative antiphospholipid syndrome. Ann Rheum Dis 2003; 62: 1127-33.
37. Sengle SR, D'Cruz DP, Hughes GR. Seronegative antiphospholipid (Hughes) syndrome. Ann Rheum Dis 2005; 64: (suppl. III), 251.
38. Giron-Gonzales JA, Garcia del Rio E, Rodriguez C, et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004; 31: 1560-7.